[go: up one dir, main page]

AR089019A1 - Derivados modificados de 4-fenil-piridina - Google Patents

Derivados modificados de 4-fenil-piridina

Info

Publication number
AR089019A1
AR089019A1 ARP120104473A ARP120104473A AR089019A1 AR 089019 A1 AR089019 A1 AR 089019A1 AR P120104473 A ARP120104473 A AR P120104473A AR P120104473 A ARP120104473 A AR P120104473A AR 089019 A1 AR089019 A1 AR 089019A1
Authority
AR
Argentina
Prior art keywords
nr101r102
alkyl
optionally substituted
formula
group
Prior art date
Application number
ARP120104473A
Other languages
English (en)
Inventor
Lovati Emanuela
Cannella Roberta
Venturini Alessio
Fadini Luca
Manini Peter
J Stella Valentino
Giuliano Claudio
Pietra Claudio
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48094815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089019(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of AR089019A1 publication Critical patent/AR089019A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/025—Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula (1), también conocidos como derivados de 4-fenil-piridina, son particularmente útiles para la prevención y/o tratamiento le enfermedades que están relacionados de manera patofisiológica con el receptor NK1 en un paciente Por consiguiente, en otra aplicación, la presente proporciona un método de tratamiento de una enfermedad mediada por el receptor NK1 que consiste en administrar a dicho paciente una cantidad terapéuticamente eficaz de un compuesto con fórmula (1) o una sal, o un aducto del mismo, también farmacéuticamente aceptable. También se describen los preparados farmacéuticos para prevenir y/o tratar enfermedades relacionadas pato-fisiológicamente con el receptor NK1 en un paciente, lo que comprende una cantidad terapéuticamente eficaz de un compuesto con formula (1) o una sal o aducto del mismo farmacéuticamente aceptable. y uno o más excipientes también farmacéuticamente aceptables. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable o su aducto, en el que R se selecciona del grupo que comprende hidrógeno, hidroxi, hidroxialquilo, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, -OR¹⁰¹, -NR¹⁰¹R¹⁰², -NR¹⁰¹C(O)R¹⁰², -C(O)R¹⁰¹, -C(O)OR¹⁰¹, -C(O)NR¹⁰¹R¹⁰², -alquil-NR¹⁰¹R¹⁰², -S(O)₂R¹⁰², -SR¹⁰¹, -S(O)₂NR¹⁰¹R¹⁰², arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y heteroarilalquilo, cada uno opcionalmente sustituido de manera independiente por uno o más sustituyentes independientes R¹⁰³; R¹ y R² se seleccionan de manera independiente del grupo que comprende hidrógeno, hidroxi, hidroxialquilo, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, -OR¹⁰¹, -NR¹⁰¹R¹⁰², -NR¹⁰¹C(O)R¹⁰², -C(O)R¹⁰¹, -C(O)OR¹⁰¹, -C(O)NR¹⁰¹R¹⁰², -alquil-NR¹⁰¹R¹⁰², -S(O)₂R¹⁰², -SR¹⁰¹, -S(O)₂NR¹⁰¹R¹⁰², arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y heteroarilalquilo, cada uno opcionalmente sustituido de manera independiente por uno o más sustituyentes independientes R¹⁰³; o R¹ junto a los átomos y/u otro(s) sustituyente(s) en el mismo anillo de fenilo, forman un anillo carbocíclico heterocíclico o monocíclico, bicíclico o tricíclico, fusionado o no, que se sustituye opcionalmente de manera independiente por uno o más sustituyentes R¹⁰³; o R² junto a los átomos y/u otro(s) sustituyente(s) en el mismo anillo de fenilo, forman un anillo carbocíclico heterocíclico o monocíclico, bicíclico o tricíclico, fusionado o no, que se sustituye opcionalmente de manera independiente por uno o más sustituyentes R¹⁰³; R³ y R⁴ se seleccionan de manera independiente del grupo que comprende hidrógeno, hidroxi, hidroxialquilo, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, -OR¹⁰¹, -NR¹⁰¹R¹⁰², -NR¹⁰¹C(O)R¹⁰², -C(O)R¹⁰¹, -C(O)OR¹⁰¹, -C(O)NR¹⁰¹R¹⁰², -alquiI-NR¹⁰¹R¹⁰², -S(O)₂R¹⁰², -SR¹⁰¹, -S(O)₂NR¹⁰¹R¹⁰², arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y heteroarilalquilo, cada uno opcionalmente sustituido de manera independiente por uno o más sustituyentes independientes R¹⁰³; o R³ y R⁴ junto a los átomos conectando el mismo anillo de fenilo, forman un anillo carbocíclico, heterocíclico o monocíclico, bicíclico o tricíclico, fusionado o no, que se sustituye opcionalmente de manera independiente por uno o más sustituyentes R¹⁰³; R⁵ y R⁶ se seleccionan de manera independiente del grupo que comprende hidrógeno, hidroxi, hidroxialquilo, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, -OR¹⁰¹, -NR¹⁰¹R¹⁰², -NR¹⁰¹C(O)R¹⁰², -C(O)R¹⁰¹, -C(O)OR¹⁰¹, -C(O)NR¹⁰¹R¹⁰², -alquil-NR¹⁰¹R¹⁰², -S(O)₂R¹⁰², -SR¹⁰¹, -S(O)₂NR¹⁰¹R¹⁰², arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y heteroarilalquilo, cada uno opcionalmente sustituido de manera independiente por uno o más sustituyentes independientes R¹⁰³; X se selecciona del grupo que comprende -C(O) NR¹⁰¹R¹⁰², alquil-O-, -alquil-NR¹⁰¹R¹⁰², -NR¹⁰¹C(O) y -NR¹⁰¹-alquilo, cada uno opcionalmente sustituido de manera independiente por uno o más sustituyentes independientes R¹⁰³; Y se selecciona del grupo que comprende -NR¹⁰¹R¹⁰², -NR¹⁰¹-alquil-OH, NR¹⁰¹S(O)₂alquilo, -NR¹⁰¹S(O)₂fenilo, -N=CH-NR¹⁰¹R¹⁰², heterocicloalquilo y heterocicloalquilalquilo, cada uno opcionalmente sustituido de manera independiente por uno o más sustituyentes independientes R¹⁰³; Z es una fórmula estructural que se selecciona del grupo de formula (1a) a (1i), lo que la fórmula (1a) refiere como un óxido; R¹⁰⁰, R¹⁰⁰, R¹⁰¹, R¹⁰² y R¹⁰³ se selecciona cada uno de manera independiente del grupo que comprende hidrógeno, ciano, -NO₂, -OR¹⁰⁴, óxido, hidroxi, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, -C(O)R¹⁰⁴, -C(O)OR¹⁰⁴, -C(O)NR¹⁰⁴R¹⁰⁵, -NR¹⁰⁴R¹⁰⁵, -NR¹⁰⁴S(O)₂R¹⁰⁵, -NR¹⁰⁴C(O)R¹⁰⁵, -S(O)₂R¹⁰⁴, -SR¹⁰⁴ y S(O)₂NR¹⁰⁴R¹⁰⁵, cada uno opcionalmente sustituido de manera independiente por uno o más sustituyentes independientes R¹⁰³; o R¹⁰¹, R¹⁰², junto a los átomos conectando el mismo, forman un anillo carbocíclico heterocíclico o monocíclico, bicíclico o tricíclico, fusionado o no, que se sustituye opcionalmente de manera independiente por uno o más sustituyentes R¹⁰³; o R¹⁰⁰, R¹⁰⁰, junto a los átomos, conectando el mismo, forman un anillo carbocíclico heterocíclico o monocíclico, bicíclico o tricíclico, fusionado o no, que se sustituye opcionalmente de manera independiente por uno o más sustituyentes R¹⁰³; R¹⁰⁴ y R¹⁰⁵ se seleccionan de manera independiente del grupo que comprende hidrógeno, ciano, -NO₂, hidroxi, óxido, hidroxialquilo, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y heteroarilalquilo; m es de 0 a 4; n es de 0 a 5; p es de 0 a 1; y con la condición de que, si está presente en el compuesto de fórmula (1) un nopiridina-N-óxido (N⁻®O⁺), entonces es más de uno, el número total de N-óxido en el compuesto de fórmula (1).
ARP120104473A 2011-11-29 2012-11-29 Derivados modificados de 4-fenil-piridina AR089019A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564537P 2011-11-29 2011-11-29
US13/478,361 US8426450B1 (en) 2011-11-29 2012-05-23 Substituted 4-phenyl pyridines having anti-emetic effect

Publications (1)

Publication Number Publication Date
AR089019A1 true AR089019A1 (es) 2014-07-23

Family

ID=48094815

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104473A AR089019A1 (es) 2011-11-29 2012-11-29 Derivados modificados de 4-fenil-piridina

Country Status (50)

Country Link
US (7) US8426450B1 (es)
EP (1) EP2785706B1 (es)
JP (3) JP5635708B2 (es)
KR (1) KR101979050B1 (es)
CN (6) CN104053652A (es)
AP (1) AP2014007729A0 (es)
AR (1) AR089019A1 (es)
AU (1) AU2012346133B2 (es)
BR (1) BR112014012878B1 (es)
CA (1) CA2850644C (es)
CL (1) CL2014001280A1 (es)
CO (1) CO6990728A2 (es)
CR (1) CR20140312A (es)
CY (2) CY1118416T1 (es)
DK (1) DK2785706T3 (es)
DO (1) DOP2014000115A (es)
EA (1) EA026553B1 (es)
EC (1) ECSP14003642A (es)
ES (1) ES2603958T3 (es)
FI (1) FIC20200022I1 (es)
FR (1) FR20C1029I2 (es)
GE (1) GEP201706695B (es)
GT (1) GT201400102A (es)
HR (1) HRP20161708T1 (es)
HU (2) HUE032288T2 (es)
IL (1) IL232859B (es)
IN (1) IN2014CN04907A (es)
JO (1) JO3202B1 (es)
LT (2) LT2785706T (es)
MA (1) MA35836B1 (es)
MD (1) MD4539C1 (es)
ME (1) ME02561B (es)
MX (1) MX2014006423A (es)
MY (1) MY165514A (es)
NI (1) NI201400043A (es)
NL (1) NL301047I2 (es)
PE (1) PE20141421A1 (es)
PH (1) PH12014501199B1 (es)
PL (1) PL2785706T3 (es)
PT (1) PT2785706T (es)
RS (1) RS55448B1 (es)
SG (1) SG11201402044XA (es)
SI (1) SI2785706T1 (es)
SM (2) SMT201600467T1 (es)
TN (1) TN2014000165A1 (es)
TW (1) TWI638806B (es)
UA (1) UA115136C2 (es)
UY (1) UY34472A (es)
WO (1) WO2013082102A1 (es)
ZA (1) ZA201404787B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
EP2648931B1 (en) 2010-12-07 2017-02-01 Allison Transmission, Inc. Energy storage system for hybrid electric vehicle
PL2723732T3 (pl) 2011-06-22 2017-07-31 Purdue Pharma Lp Antagoniści trpv1 z podstawnikiem dihydroksylowym oraz ich zastosowania
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
KR20160078997A (ko) 2013-11-08 2016-07-05 깃세이 야쿠힌 고교 가부시키가이샤 카복시메틸피페리딘 유도체
WO2015171489A1 (en) * 2014-05-05 2015-11-12 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
KR102336926B1 (ko) 2014-10-06 2021-12-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
US10005803B2 (en) * 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PT3435980T (pt) * 2016-06-06 2020-02-21 Helsinn Healthcare Sa Formulações injetáveis fisiologicamente equilibradas de fosnetupitant
UA124708C2 (uk) 2016-09-30 2021-11-03 Вертекс Фармасьютікалз Інкорпорейтед Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора
AU2017371200B2 (en) 2016-12-09 2021-05-06 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN108619525B (zh) * 2017-03-15 2020-12-29 和龙 奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
KR102606188B1 (ko) 2017-08-02 2023-11-23 버텍스 파마슈티칼스 인코포레이티드 피롤리딘 화합물을 제조하기 위한 공정
CN107698500A (zh) * 2017-10-17 2018-02-16 扬子江药业集团四川海蓉药业有限公司 一种奈妥匹坦的制备方法
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
SI3737378T1 (sl) * 2018-01-12 2023-06-30 Orion Corporation Kapljice palonosetrona za oči za zdravljenje ali preprečevanje slabosti in bruhanja
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
CN112778370B (zh) * 2019-11-06 2025-09-26 扬子江药业集团江苏海慈生物药业有限公司 一种制备福奈妥匹坦的方法
MX2022011545A (es) 2020-04-03 2022-11-09 Nerre Therapeutics Ltd Un antagonista de receptor de nk-1 para tratar una enfermedad que se selecciona de sepsis, choque septico, síndrome de dificultad respiratoria aguda (ards) 0 síndrome de disfunción orgánica múltiple (mcds).
IL298589A (en) 2020-06-02 2023-01-01 Nerre Therapeutics Ltd Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
WO2025036703A1 (en) 2023-08-13 2025-02-20 Helsinn Healthcare Sa Fosnetupitant for administration via intravenous bolus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051181B1 (en) 1997-12-31 2004-03-17 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
ES2226622T3 (es) * 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
ATE253561T1 (de) * 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
HU230316B1 (hu) 2000-07-14 2016-01-28 F. Hoffmann-La Roche Ag N-oxidok, mint 4-fenil-piridin-származékok előgyógyszerei, eljárás és előállításukra és az ezeket tartalmazó gyógyszerkészítmények
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
CN1263446C (zh) 2000-12-14 2006-07-12 弗·哈夫曼-拉罗切有限公司 自乳化脂质基质(selm)
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2602445C (en) * 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
US20090114877A1 (en) * 2005-09-13 2009-05-07 Eisai R&D Management Co., Ltd. Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA108077C2 (xx) * 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
EP2361090B1 (en) * 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CA2798172C (en) * 2010-01-07 2017-11-21 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
WO2012075396A2 (en) * 2010-12-02 2012-06-07 The University Of Kansas Prodrugs of 6-cyclohexyl-1-hydroxy-4- methylpyridin-2(1h)-one and derivatives thereof
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain

Also Published As

Publication number Publication date
US20180194788A1 (en) 2018-07-12
TW201331181A (zh) 2013-08-01
EP2785706B1 (en) 2016-09-14
CY2020017I2 (el) 2020-11-25
SMT201600467B (it) 2017-03-08
RS55448B1 (sr) 2017-04-28
GEP201706695B (en) 2017-07-10
JP5635708B2 (ja) 2014-12-03
CA2850644C (en) 2020-08-11
ES2603958T3 (es) 2017-03-02
WO2013082102A1 (en) 2013-06-06
BR112014012878A2 (pt) 2017-06-13
NL301047I1 (es) 2020-06-24
HUE032288T2 (hu) 2017-09-28
EP2785706A1 (en) 2014-10-08
DK2785706T3 (en) 2016-12-12
NI201400043A (es) 2015-09-21
FIC20200022I1 (fi) 2020-06-24
US11312698B2 (en) 2022-04-26
MA35836B1 (fr) 2014-12-01
JO3202B1 (ar) 2018-03-08
SMT201600467T1 (it) 2017-03-08
JP6023146B2 (ja) 2016-11-09
CN112979543A (zh) 2021-06-18
JP2016147868A (ja) 2016-08-18
UA115136C2 (uk) 2017-09-25
NL301047I2 (nl) 2023-08-01
HK1199030A1 (zh) 2015-06-19
US20200399240A1 (en) 2020-12-24
CO6990728A2 (es) 2014-07-10
CN111662330A (zh) 2020-09-15
EA026553B1 (ru) 2017-04-28
JP2015017121A (ja) 2015-01-29
MD4539B1 (ro) 2017-12-31
CN106986822B (zh) 2020-04-21
HUS2000032I1 (hu) 2020-09-28
TN2014000165A1 (en) 2015-09-30
JP6074083B2 (ja) 2017-02-01
UY34472A (es) 2013-06-28
PL2785706T3 (pl) 2017-03-31
GT201400102A (es) 2015-12-07
CN106986822A (zh) 2017-07-28
KR101979050B1 (ko) 2019-05-15
CY1118416T1 (el) 2017-06-28
MD20140059A2 (en) 2014-11-30
US20190177296A1 (en) 2019-06-13
DOP2014000115A (es) 2014-07-15
FR20C1029I2 (fr) 2023-12-29
US8426450B1 (en) 2013-04-23
LTC2785706I2 (lt) 2023-07-10
HRP20161708T1 (hr) 2017-02-10
ECSP14003642A (es) 2015-12-31
US20130231315A1 (en) 2013-09-05
CN104053652A (zh) 2014-09-17
LTPA2020510I1 (lt) 2020-07-10
PT2785706T (pt) 2016-12-16
LT2785706T (lt) 2016-12-12
EA201400624A1 (ru) 2015-01-30
US9908907B2 (en) 2018-03-06
US10717721B2 (en) 2020-07-21
PH12014501199A1 (en) 2014-09-08
IN2014CN04907A (es) 2015-09-18
IL232859B (en) 2018-01-31
MX2014006423A (es) 2014-09-08
AU2012346133A1 (en) 2014-04-17
FR20C1029I1 (fr) 2020-10-02
BR112014012878A8 (pt) 2021-06-15
IL232859A0 (en) 2014-07-31
SI2785706T1 (sl) 2017-01-31
US8895586B2 (en) 2014-11-25
ZA201404787B (en) 2015-12-23
CN112979543B (zh) 2024-09-24
CY2020017I1 (el) 2020-11-25
US12071421B2 (en) 2024-08-27
JP2014507446A (ja) 2014-03-27
CN106518924B (zh) 2019-10-08
US20170050993A1 (en) 2017-02-23
US10208073B2 (en) 2019-02-19
AU2012346133B2 (en) 2016-10-06
CN106518924A (zh) 2017-03-22
NZ623746A (en) 2016-07-29
PE20141421A1 (es) 2014-10-03
CL2014001280A1 (es) 2014-11-07
MY165514A (en) 2018-03-28
ME02561B (me) 2017-02-20
CA2850644A1 (en) 2013-06-06
CN112961104A (zh) 2021-06-15
TWI638806B (zh) 2018-10-21
KR20140103991A (ko) 2014-08-27
MD4539C1 (ro) 2018-07-31
CR20140312A (es) 2014-08-27
SG11201402044XA (en) 2014-09-26
PH12014501199B1 (en) 2014-09-08
CN111662330B (zh) 2023-05-12
BR112014012878B1 (pt) 2022-05-31
US20220401463A1 (en) 2022-12-22
AP2014007729A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
AR089019A1 (es) Derivados modificados de 4-fenil-piridina
AR085398A1 (es) Ureas asimetricas y usos medicos de las mismas
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
AR096339A1 (es) Agonistas del receptor de somatostatina subtipo 4 (sstr4)
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR091628A1 (es) 7h-pirrolo[2,3-d]pirimidinas 4-(amino-substituidas) como inhibidores de lrrk2
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
BR112016019462B8 (pt) Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR085750A1 (es) Derivados de pirazolo-pirimidina
BR112014032581A2 (pt) inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune
RU2013108348A (ru) Конденсированные гетероарилы и их применение
AR084731A1 (es) Derivados de imidazoquinolina sustituidos
AR091490A1 (es) Antagonistas de iap
CO2017004603A2 (es) Inhibidores de replicación del virus respiratorio inicial (rsv) derivados de 1´-[1h- 1,3-benzodiazol-2-il]metil}- espiro[ciclopropano-1,3'-indol]-2'-ona o 1´-[1h-1,3- benzodiazol-2-il]metil)espiro[ciclopropano-1,3'-pirrolo [2,3-c]piridin]'(1'h)-ona, composiciones que los comprenden y métodos de preparación
AR129378A1 (es) Compuestos de indolinilo antivirales y usos de estos

Legal Events

Date Code Title Description
FG Grant, registration